ePrints

Paclitaxel poliglumex. Antimitotic drug, Oncolytic.

Lookup NU author(s): Professor Alan Boddy

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Paclitaxel poliglumex (Xyotax (TM)) is a glutamic acid polymer formulation of paclitaxel in which the active drug is covalently bound with a loading of approximately 38% by weight of the total polymer. Preclinical studies suggested antitumor activity superior to that of equitoxic doses of native paclitaxel, as well as enhanced tumor delivery and retention of the active drug. Subsequent clinical evaluation indicated some activity, but at the expense of neurotoxicity. Clinical evaluation is ongoing, especially in lung cancer, with a specific indication that women with normal or high levels of estrogen may be particularly responsive to this drug.

Publication metadata

Author(s): Boddy, A. V.

Publication type: Article

Publication status: Published

Journal: Drugs of the Future

Year: 2007

Volume: 32

Issue: 9

Pages: 776-780

Print publication date: 01/09/2007

ISSN (print): 0377-8282

ISSN (electronic):

URL: http://dx.doi.org/10.1358/dof.2007.032.09.1125219

DOI: 10.1358/dof.2007.032.09.1125219

Altmetrics

Share